News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,622 Results
Type
Article (42328)
Company Profile (436)
Press Release (671858)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (208749)
Career Advice (2021)
Deals (36008)
Drug Delivery (104)
Drug Development (83582)
Employer Resources (173)
FDA (16433)
Job Trends (15098)
News (352812)
Policy (33084)
Tag
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (87)
Alliances (50962)
ALS (94)
Alzheimer's disease (1431)
Antibody-drug conjugate (ADC) (139)
Approvals (16424)
Artificial intelligence (268)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (330)
Bladder cancer (82)
Brain cancer (27)
Breast cancer (287)
Cancer (2316)
Cardiovascular disease (185)
Career advice (1689)
Career pathing (30)
CAR-T (157)
Cell therapy (444)
Cervical cancer (19)
Clinical research (67781)
Collaboration (877)
Compensation (532)
Complete response letters (24)
COVID-19 (2648)
CRISPR (45)
C-suite (252)
Cystic fibrosis (105)
Data (2232)
Decentralized trials (2)
Denatured (28)
Depression (50)
Diabetes (275)
Diagnostics (6427)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (107)
Drug shortages (26)
Duchenne muscular dystrophy (100)
Earnings (87849)
Editorial (40)
Employer branding (21)
Employer resources (147)
Events (115947)
Executive appointments (743)
FDA (17701)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (783)
Gene editing (113)
Generative AI (20)
Gene therapy (328)
GLP-1 (747)
Government (4503)
Grass and pollen (4)
Guidances (59)
Healthcare (19146)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (130)
Indications (30)
Infectious disease (2793)
Inflammatory bowel disease (143)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (98)
Interviews (311)
IPO (16789)
IRA (43)
Job creations (3701)
Job search strategy (1434)
Kidney cancer (10)
Labor market (38)
Layoffs (496)
Leadership (18)
Legal (7986)
Liver cancer (76)
Lung cancer (328)
Lymphoma (155)
Machine learning (7)
Management (58)
Manufacturing (313)
MASH (69)
Medical device (13526)
Medtech (13531)
Mergers & acquisitions (19758)
Metabolic disorders (718)
Multiple sclerosis (82)
NASH (19)
Neurodegenerative disease (102)
Neuropsychiatric disorders (33)
Neuroscience (2002)
NextGen: Class of 2025 (6755)
Non-profit (4550)
Now hiring (39)
Obesity (385)
Opinion (223)
Ovarian cancer (77)
Pain (89)
Pancreatic cancer (84)
Parkinson's disease (155)
Partnered (21)
Patents (236)
Patient recruitment (111)
Peanut (47)
People (58681)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21298)
Phase II (29908)
Phase III (22115)
Pipeline (1209)
Policy (146)
Postmarket research (2601)
Preclinical (9138)
Press Release (67)
Prostate cancer (110)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (404)
Real estate (6015)
Recruiting (66)
Regulatory (22739)
Reports (46)
Research institute (2416)
Resumes & cover letters (351)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (76)
Series A (139)
Series B (90)
Service/supplier (11)
Sickle cell disease (57)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3762)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (39)
The Weekly (48)
Vaccines (705)
Venture capitalists (43)
Weight loss (255)
Women's health (37)
Worklife (17)
Date
Today (177)
Last 7 days (889)
Last 30 days (2698)
Last 365 days (33835)
2025 (10903)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54921)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (58)
Alaska (7)
Arizona (239)
Arkansas (14)
Asia (39258)
Australia (6532)
California (6240)
Canada (2022)
China (533)
Colorado (272)
Connecticut (286)
Delaware (149)
Europe (85804)
Florida (911)
Georgia (206)
Idaho (57)
Illinois (553)
India (25)
Indiana (310)
Iowa (12)
Japan (163)
Kansas (107)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (908)
Massachusetts (4741)
Michigan (221)
Minnesota (397)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (67)
New Jersey (1757)
New Mexico (30)
New York (1761)
North Carolina (1033)
North Dakota (8)
Northern California (2699)
Ohio (206)
Oklahoma (14)
Oregon (38)
Pennsylvania (1389)
Puerto Rico (12)
Rhode Island (34)
South America (1110)
South Carolina (22)
South Dakota (1)
Southern California (2330)
Tennessee (101)
Texas (924)
United States (23638)
Utah (183)
Virginia (149)
Washington D.C. (63)
Washington State (574)
West Virginia (3)
Wisconsin (55)
714,622 Results for "esperion therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients.
March 22, 2024
·
10 min read
Policy
Daiichi Sankyo to Pay Esperion $125M in Settlement of Milestone Payment Lawsuit
Wednesday’s settlement resolves a legal dispute between Daiichi Sankyo Europe and Esperion Therapeutics regarding milestone payments under their cardiovascular drug collaboration.
January 4, 2024
·
2 min read
·
Tyler Patchen
FDA
Esperion Targets Seven-Fold Jump in Cholesterol Drug Population with FDA Label Expansion
Esperion bagged broader-than-expected FDA labels for its cholesterol-busting drugs Friday, allowing the biotech to target seven times as many people in the U.S. compared to the old labels.
March 25, 2024
·
2 min read
·
Nick Paul Taylor
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
April 3, 2025
·
4 min read
Press Releases
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
April 30, 2025
·
8 min read
Press Releases
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
March 26, 2025
·
4 min read
Press Releases
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
April 9, 2025
·
6 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025
April 21, 2025
·
4 min read
Drug Development
Esperion-Daiichi Sankyo Partnership Saga Continues with Payment Spat
For Daiichi Sankyo, recent results from the Phase III CLEAR trial of Esperion Therapeutics’ Nexletol (bempedoic acid) were not convincing enough to trigger a milestone payment.
March 17, 2023
·
2 min read
·
Tristan Manalac
1 of 71,463
Next
